Cyclosporine-associated hypertension in cardiopulmonary transplantation. The beneficial effect of nifedipine on renal function.
In a retrospective review of fifty heart, lung, and heart-lung recipients receiving cyclosporine, forty-six (92%) were hypertensive. This hypertension was managed with either prazosin (n = 29) or nifedipine (n = 17). Renal function was assessed by creatinine clearance estimation and found to be significantly better in those patients receiving nifedipine. (creatinine clearance = 60 ml/min [SEM 5.7] vs. 49 ml/min [SEM 2.7]; P less than 0.05). This observation suggests that nifedipine should be the drug of choice for the treatment of cyclosporine-associated hypertension in cardiac and pulmonary transplant recipients.
Kirk
A J
AJ
Cardiopulmonary Transplant Unit, Freeman Hospital, High Heaton, Newcastle upon Tyne, United Kingdom.
Omar
I
I
Bateman
D N
DN
Dark
J H
JH
D000328:Adult; D003524:Cyclosporins / Q000009:adverse effects*; D016027:Heart Transplantation; D006801:Humans; D006973:Hypertension / Q000139:chemically induced*; D007668:Kidney / Q000502:physiology; D008055:Lipids / Q000097:blood; D016040:Lung Transplantation; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*; D011224:Prazosin / Q000627:therapeutic use; D012189:Retrospective Studies
D003524:Cyclosporins; D008055:Lipids; D009543:Nifedipine; D011224:Prazosin